Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia

Dopamine replacement therapy for the treatment of Parkinsonʼs disease leads to deleterious abnormal involuntary movements (AIMs), known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia, which parallels enhanced striatal dopamine D1 receptor-mediated signaling. Recent evidence suggests sti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuroreport 2009-09, Vol.20 (14), p.1265-1269
Hauptverfasser:	Eskow Jaunarajs, Karen L, Dupre, Kristin B, Steiniger, Aimee, Klioueva, Anna, Moore, Alexander, Kelly, Catherine, Bishop, Christopher
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic Agents Animals Benzazepines - toxicity Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dopamine Agonists - toxicity Dyskinesia, Drug-Induced - drug therapy Levodopa - adverse effects Male Medical sciences Motor Activity - drug effects Nervous system (semeiology, syndromes) Nervous system as a whole Neurology Oxidopamine - toxicity Parkinsonian Disorders - chemically induced Pyridines - pharmacology Rats Rats, Sprague-Dawley Receptors, Dopamine D1 - agonists Receptors, Dopamine D1 - metabolism Serotonin 5-HT1 Receptor Agonists Serotonin Receptor Agonists - pharmacology Severity of Illness Index Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!